Drug intelligence / Profile preview

Ad5-CMV-mTNFa

Development stage
Preclinical
Lead developer
University of Alabama at Birmingham
Modality
Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration
Intratumoral
01

Overview

Ad5-CMV-mTNFa is a replication-deficient adenoviral vector (serotype 5) designed to deliver the murine tumor necrosis factor-alpha (mTNF-α) gene under the control of the constitutive cytomegalovirus (CMV) promoter. TNF-α is a potent cytokine that induces apoptosis in cancer cells, activates the vascular endothelium, and stimulates the immune system. By utilizing an adenoviral vector, researchers can achieve high levels of localized TNF-α expression within the tumor microenvironment, which aims to maximize anti-tumor efficacy while minimizing the systemic toxicity typically associated with recombinant TNF-α protein administration. This construct is primarily used as a research tool in preclinical oncology to study the effects of localized cytokine therapy and its synergy with other modalities such as radiotherapy or chemotherapy in syngeneic mouse models.

Other names
Adenoviral mouse TNF-alphaAd-mTNF-alpha
02

Targets

TNFR2 (Tumor necrosis factor receptor superfamily member 1B)CAR (Chimeric antigen receptor)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))Neuraminidase

Beyond the preview

Go deeper on Ad5-CMV-mTNFa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad5-CMV-mTNFa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call